16 February 2022 - Merck announced today that the EMA’s CHMP has recommended the approval of Vaxneuvance (pneumococcal 15 valent conjugate vaccine) for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.

The CHMP opinion was based on data from eight randomised, double-blind clinical trials that enrolled approximately 8,400 individuals from a variety of paediatric populations and clinical circumstances; of these, approximately 5,400 received Vaxneuvance.

Read Merck/MSD press release